HOME
 
  • BURDEN OF DISEASE
    • Rare diseases
    • Lysosomal storage diseases
    • Gaucher disease
      • Gaucher disease Type 1
      • Gaucher disease Type 2
      • Gaucher disease Type 3
    • Genetic inheritance
    • Epidemiology
      • Gaucher disease in the Ashkenazi Jewish population
      • Age at disease onset and life expectancy
    • Comorbidities
      • Haematological malignancies
      • Neurological disorders
      • Metabolic disorders
      • Immunological disorders
      • Gastrointestinal disorders
    • Quality of life
  • DIFFERENTIAL DIAGNOSIS
    • Signs and symptoms of Gaucher disease
    • Getting the diagnosis right
    • Diagnosis of Gaucher disease
      • Diagnostic algorithms
      • Disease severity indexes
      • Glucocerebrosidase
      • Glucosylsphingosine (lyso-Gb1)
      • Chitotriosidase
      • CC chemokine ligand 18 (CCL18)
      • Diagnostic imaging
      • Carrier testing and prenatal and newborn screening
  • DISEASE MANAGEMENT
    • Patient-centric management
      • Management of Gaucher disease Type 1
      • Management of Gaucher disease Types 2 and 3
      • Pregnancy and Gaucher disease
      • Support and counselling for Gaucher disease
    • Enzyme replacement therapy
      • Imiglucerase
      • Velaglucerase alfa
      • Taliglucerase alfa
    • Substrate reduction therapy
      • Miglustat
      • Eliglustat
  • MEETINGS & EVENTS
    • 2022 WORLDSymposium 2022
    • ICIEM 2021
    • 2021 WORLDSymposium 2021
      • WORLDSymposium 2021 Day 1
      • WORLDSymposium 2021 Day 2
      • WORLDSymposium 2021 Day 3
      • WORLDSymposium 2021 Day 4
    • EWGGD 2020
    • Key congress calendar 2022
  • PUBLICATION & EXPERT INSIGHT
HOME
 
  • BURDEN OF DISEASE
    • Rare diseases
    • Lysosomal storage diseases
    • Gaucher disease
      • Gaucher disease Type 1
      • Gaucher disease Type 2
      • Gaucher disease Type 3
    • Genetic inheritance
    • Epidemiology
      • Gaucher disease in the Ashkenazi Jewish population
      • Age at disease onset and life expectancy
    • Comorbidities
      • Haematological malignancies
      • Neurological disorders
      • Metabolic disorders
      • Immunological disorders
      • Gastrointestinal disorders
    • Quality of life
  • DIFFERENTIAL DIAGNOSIS
    • Signs and symptoms of Gaucher disease
    • Getting the diagnosis right
    • Diagnosis of Gaucher disease
      • Diagnostic algorithms
      • Disease severity indexes
      • Glucocerebrosidase
      • Glucosylsphingosine (lyso-Gb1)
      • Chitotriosidase
      • CC chemokine ligand 18 (CCL18)
      • Diagnostic imaging
      • Carrier testing and prenatal and newborn screening
  • DISEASE MANAGEMENT
    • Patient-centric management
      • Management of Gaucher disease Type 1
      • Management of Gaucher disease Types 2 and 3
      • Pregnancy and Gaucher disease
      • Support and counselling for Gaucher disease
    • Enzyme replacement therapy
      • Imiglucerase
      • Velaglucerase alfa
      • Taliglucerase alfa
    • Substrate reduction therapy
      • Miglustat
      • Eliglustat
  • MEETINGS & EVENTS
    • 2022 WORLDSymposium 2022
    • ICIEM 2021
    • 2021 WORLDSymposium 2021
      • WORLDSymposium 2021 Day 1
      • WORLDSymposium 2021 Day 2
      • WORLDSymposium 2021 Day 3
      • WORLDSymposium 2021 Day 4
    • EWGGD 2020
    • Key congress calendar 2022
  • PUBLICATION & EXPERT INSIGHT

SITE MAP

HOME

BURDEN OF DISEASE

Rare diseases

Lysosomal storage diseases

Gaucher disease

  • Gaucher disease Type 1
  • Gaucher disease Type 2
  • Gaucher disease Type 3

Genetic inheritance of Gaucher disease

Epidemiology of Gaucher disease

  • Gaucher disease in the Ashkenazi Jewish population
  • Age at disease onset and life expectancy

Comorbidities

  • Haematological malignancies
  • Neurological disorders
  • Metabolic disorders
  • Immunological disorders
  • Gastrointestinal disorders

Gaucher disease and quality of life

DIFFERENTIAL DIAGNOSIS

Signs and symptoms of Gaucher disease

Getting the diagnosis right

Diagnosis of Gaucher disease

  • Diagnostic algorithms
  • Disease severity indexes
  • Glucocerebrosidase
  • Glucosylsphingosine (lyso-Gb1)
  • Chitotriosidase
  • CC chemokine ligand 18 (CCL18)
  • Diagnostic imaging
  • Carrier testing and prenatal and newborn screening

DISEASE MANAGEMENT

Patient-centric management

  • Management of Gaucher disease Type 1
  • Management of Gaucher disease Types 2 and 3
  • Pregnancy and Gaucher disease
  • Support and counselling for Gaucher disease

Enzyme replacement therapy

  • Imiglucerase
  • Velaglucerase alfa
  • Taliglucerase alfa

Substrate reduction therapy

  • Miglustat
  • Eliglustat

MEETINGS & EVENTS

  • Key congress calendar 2022

TAKEDA'S COMMITMENT TO RARE DISEASES

GAUCHER DISEASE RESOURCES BY TAKEDA

SEARCH

CONTACT US

PRIVACY POLICY

TERMS OF USE

SITEMAP

C-ANPROM/INT//7572; Date of preparation: September 2020

Takeda aspires to transform the treatment of rare diseases, including lysosomal storage disorders

Takeda's commitment to Rare diseases

Gaucher disease resources by Takeda

Contact us

    BURDEN OF DISEASE
    • Rare diseases
    • Lysosomal storage diseases
    • Gaucher disease
    • Genetic inheritance
    • Epidemiology
    • Comorbidities
    • Quality of life
    DIFFERENTIAL DIAGNOSIS
    • Signs and symptoms of Gaucher disease
    • Getting the diagnosis right
    • Diagnosis of Gaucher disease
    DISEASE MANAGEMENT
    • Patient-centric management
    • Enzyme replacement therapy
    • Substrate reduction therapy
    MEETINGS & EVENTS
    • 2022 WORLDSymposium 2022
    • ICIEM 2021
    • 2021 WORLDSymposium 2021
    • EWGGD 2020
    • Key congress calendar 2022
    PUBLICATION & EXPERT INSIGHT

CONNECT WITH US:

Copyright 2022 Takeda Pharmaceutical Company Limited. All rights reserved.

This website provides educational resources intended for healthcare professionals outside the US and the UK with an interest in Gaucher disease.

Last updated: December 2022

You are now leaving https://gaucher-institute.com/

By following this link you will be leaving the Gaucher Institute website. Please note that Takeda does not take responsibility for the content displayed on other websites.

Return to https://gaucher-institute.com/
  • PRIVACY POLICY
  • TERMS OF USE
  • SITEMAP

COOKIE POLICY

The site uses cookies to provide you with more responsive and personalised services and to analyse site traffic. By using this site, you accept our use of cookies as described in our privacy notice. Please read our privacy notice for more information on the cookies we use, the processing of your | LEARN MORE | personal data and how to delete or block the use of cookies.

I ACCEPT